Estimating the prevalence of *Trichomonas vaginalis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and human papillomavirus infection in indigenous women in northern Australia

Francis J Bowden, Barbara A Paterson, Jacki Mein, Jan Savage, Christopher K Fairley, Suzanne M Garland, Sepehr N Tabrizi

**Objective:** To estimate more accurately the age specific prevalence of *Trichomonas vaginalis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and human papillomavirus infection (HPV) in indigenous women living in urban, rural, and remote areas of the “Top End” of the Northern Territory (NT).

**Design:** Analysis of data obtained from two community based studies using self administered tampon specimens tested by polymerase chain reaction for sexually transmitted disease (STD). Data pertaining to the notifiable STDs (*N gonorrhoeae* and *C trachomatis*) were obtained from the NT health department.

**Patients:** 1090 indigenous women (age range 12–73 years) were enrolled when they attended local community health centres, family planning clinics, and STD clinics. The majority attended clinics in their home community in the course of “well women’s checks” which encourage women to undergo screening for a variety of general medical conditions.

**Results:** The overall prevalence of *T vaginalis*, *C trachomatis*, *N gonorrhoeae*, and HPV was 0.25 (95% CI: 0.22–0.28), 0.11 (0.09–0.13), 0.17 (0.15–0.19), and 0.42 (0.37–0.48) respectively. Of the women found to be infected (excluding HPV), 25.5% had two or more of the above organisms detected. There was a statistically significant increase in the age specific prevalence of *T vaginalis* but a significant decrease with age for *C trachomatis* and HPV infection. There was no statistically significant change for *N gonorrhoeae* with age.

**Conclusions:** STDs are hyperendemic in this population of indigenous women and the notification data significantly underestimate their prevalence. Distinct patterns of age specific prevalence were demonstrated, highlighting the need to tailor control strategies to specific epidemiological features.

(Sex Transm Inf 1999;75:431–434)

**Keywords:** sexually transmitted diseases; Australia; indigenous women

**Introduction**

The incidence of sexually transmitted diseases (STD) in the rural and remote populations of northern Australia is markedly higher than the Australian national average (Communicable Diseases Network—Australia New Zealand—National Notifiable Diseases Network, personal communication). We have suggested that one of the main reasons for this disparity is lack of access to, and utilisation of, diagnostic and treatment services in these areas. The design of appropriate indigenous health programmes to help to redress this imbalance must be guided by an understanding of the epidemiology of the diseases in question but there are few published community based data available to assist this process. Previous estimates of the burden of STDs in the Northern Territory (NT) have been based primarily on notification data which are collected by the NT health department. These data are derived from the public and private laboratories in the NT for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*, and from a combination of clinician and laboratory sources for donovanosis and syphilis. Infections caused by *Trichomonas vaginalis* and human papillomavirus are not notifiable.

It is recognised that notification data can underestimate the true incidence of disease in a population for several reasons. In the case of STDs in small communities, people with symptoms may be reluctant to present for testing and, if they do, empirical therapy may be instituted without recourse to definitive diagnosis. In addition, as most STD infections are clinically silent, the bulk of disease detection is obtained during such screening. Information obtained during such screening may not be recorded accurately in the notification data and, as a result, marginalised subpopulations at particular risk of STD may be systematically excluded from the reporting system. Case definitions may exclude disease cases if made too strict—for example, syphilis serology interpretation. Clinician based reporting systems may be very unreliable, even if disease is correctly diagnosed, because of workload issues and the low priority given to reporting responsibilities. Laboratory based reporting systems improve the case acquisition for some infections (for example, *N gonorrhoeae*) but may still underestimate the prevalence of STDs which are diagnosed clinically (for example, genital warts), require potentially uncomfortable examinations.
Table 1  Proportion of women infected with Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and human papillomavirus by age group

<table>
<thead>
<tr>
<th>Age group</th>
<th>Trichomonas vaginalis (95% CI)</th>
<th>Chlamydia trachomatis (95% CI)</th>
<th>Neisseria gonorrhoeae (95% CI)</th>
<th>Human papillomavirus* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11–15</td>
<td>0.28 (0.16–0.44)</td>
<td>0.20 (0.09–0.34)</td>
<td>0.28 (0.16–0.44)</td>
<td>0.5 (0.12–0.88)</td>
</tr>
<tr>
<td>16–20</td>
<td>0.18 (0.13–0.24)</td>
<td>0.15 (0.11–0.21)</td>
<td>0.17 (0.12–0.23)</td>
<td>0.62 (0.47–0.76)</td>
</tr>
<tr>
<td>21–30</td>
<td>0.23 (0.19–0.27)</td>
<td>0.10 (0.10–0.13)</td>
<td>0.19 (0.15–0.22)</td>
<td>0.42 (0.34–0.5)</td>
</tr>
<tr>
<td>&gt;40</td>
<td>0.39 (0.31–0.49)</td>
<td>0.05 (0.02–0.11)</td>
<td>0.14 (0.08–0.21)</td>
<td>0.23 (0.12–0.37)</td>
</tr>
<tr>
<td>All ages</td>
<td>0.25 (0.22–0.28)</td>
<td>0.11 (0.09–0.13)</td>
<td>0.17 (0.15–0.19)</td>
<td>0.42 (0.37–0.48)</td>
</tr>
</tbody>
</table>

*HPV was not tested for in all cases; n (all ages) = 328; n (11–15) = 6; n (16–20) = 45; n (20–30) = 156; n (31–40) = 73; n (>40) = 48.

Results

The overall prevalence of *T vaginalis*, *C trachomatis*, *N gonorrhoeae*, and detectable HPV DNA was 0.25 (95% CI: 0.22–0.28), 0.11 (0.09–0.13), 0.17 (0.15–0.19), and 0.42 (0.37–0.48) respectively. Of the women found to have *T vaginalis*, *C trachomatis*, or *N gonorrhoeae*, 0.25 had two or more of the above organisms detected (data not shown).

The age specific prevalence data are shown in table 1 and figure 1.

There was a statistically significant decrease in the prevalence with age of *C trachomatis* (p=0.012) and detectable HPV DNA (p=0.004) but this was not demonstrated for *N gonorrhoeae* (p=0.07). There was a statistically significant increase in the prevalence of *T vaginalis* with age (p<0.001).

Notification data for 1996 were obtained from the notification records of Disease Control, Territory Health Services, Darwin. Demographic information was taken from the 1996 census, Australian Bureau of Statistics.6 χ² calculations and 95% confidence intervals were calculated using EPI-INFO 6 software.9

Methods

Permission to undertake these studies was obtained from the relevant local ethics committee. The original study population consisted of women living in urban, rural, and remote regions of the so called “Top End” of the NT, a large geographical area encompassing the Darwin, Katherine, and East Arnhem regions.

Women were asked to participate in the study when they attended local community health centres, family planning clinics, and STD clinics. More than 80% of women attended clinics in their home community in the course of “well women’s checks” which encourage women to undergo screening for a variety of general medical conditions.

Women were screened for *N gonorrhoeae*, *C trachomatis*, *T vaginalis*, and human papillomavirus (HPV) by polymerase chain reaction (PCR) testing of a self inserted tampon. The methodology employed, described elsewhere,9 has been shown to be highly sensitive and specific and to be highly acceptable to the patient.

Notification data for 1996 were obtained from the notification records of Disease Control, Territory Health Services, Darwin. Demographic information was taken from the 1996 census, Australian Bureau of Statistics.6 χ² calculations and 95% confidence intervals were calculated using EPI-INFO 6 software.9

Table 2  Notifications of Chlamydia trachomatis and Neisseria gonorrhoeae in indigenous women in the NT, 1996* and estimated “true” number of cases in indigenous female population

<table>
<thead>
<tr>
<th></th>
<th>Number of cases notified*</th>
<th>Estimated incidence‡</th>
<th>Study prevalence</th>
<th>Estimated “true” number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia trachomatis</td>
<td>418</td>
<td>250/100 000/year</td>
<td>0.11</td>
<td>2860</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>623</td>
<td>370/100 000/year</td>
<td>0.17</td>
<td>1840</td>
</tr>
</tbody>
</table>

*Notification data from Disease Control, Territory Health Services, Darwin, NT.

‡Population estimate of indigenous NT women >14 years of age derived from Australian Bureau of Statistics.6
Prevalence of T vaginalis, C trachomatis, N gonorrhoeae, and HPV infection in indigenous women in Australia

Discussion

This study shows that four STDs, N gonorrhoeae, C trachomatis, T vaginalis, and HPV, are common among indigenous women in the Top End of the NT. One study has shown the prevalence of C trachomatis and/or N gonorrhoeae in males in central Australia to be 20.9%. More than 80% of the women in this study underwent screening in the course of community-based activities. Women living in remote and rural settings were encouraged to attend for a well women’s check which includes screening for hypertension, diabetes, STDs, cervical and breast cancer. Only 9.2% of women attended because of symptoms. It is possible that this type of screening results in an underrepresentation of high risk women who, for a number of complex sociocultural reasons, may not attend under these circumstances, leading to an underestimation of the prevalence of some STDs.

It is noteworthy that more than 90% of the women involved in the study were unaware of any abnormal genital symptoms at the time of screening.10

Hyperendemic levels of T vaginalis were detected in women in the Top End of the NT. Apart from the discomfort of symptomatic disease, T vaginalis is associated with premature rupture of membranes and premature labour11 and may increase the transmission of HIV.12

The only other study of T vaginalis in northern Australia estimated the prevalence in indigenous women at 10%, based on laboratory records of conventional methods (culture and microscopy).13 Our study used a more sensitive diagnostic technique, and a more representative population sample, and estimated the prevalence to be 25%, which is consistent with other studies in disadvantaged populations in which the prevalence ranges from 24.7% to 49%.14 In our studies T vaginalis was detected in less than 1% of non-indigenous women (data not shown), most likely reflecting differences in the opportunity for diagnosis and treatment and health seeking behaviour over many years between the two groups.1

The increase in prevalence of the condition with age is of considerable interest as it is not seen in the other STDs. However, studies from the United States and Papua New Guinea have shown similar age specific prevalences,10–12 a feature consistent with a disease with a very long duration of infection. Before the development of metronidazole, trichomoniasis in women was considered to be a disease of indefinite duration if not treated with local vaginal therapies and volunteer inoculation studies in men showed that infection could persist for many months.21

The overall prevalence of infection with C trachomatis was 0.11, with a rate of 0.2 in 11–15 year old group and 0.15 in the 16–20 year old group, which fell to 0.05 in the >40 year old group. The difference between the 16–20 year old group and >40 year old group was statistically significant. As was expected, the prevalence was highest in the younger age groups (11–30). We have shown that pelvic inflammatory disease caused by C trachomatis is an important problem in the NT22 and the high prevalence results of this study are therefore not surprising.

Neisseria gonorrhoeae was also common in the population sample with an overall prevalence of 0.17 but there were no statistically significant differences in prevalence observed in the different age groups.

A non-age stratified breakdown of the HPV subtypes found in this population has been published elsewhere.23 The analysis presented here suggests that detectable HPV DNA (a marker of HPV infection, one of the major risk factors for cervical neoplasia), is acquired early by indigenous women but prevalence slowly decreases with age.

Recently, a broadly based indigenous sexual health strategy which includes educational, diagnostic, and treatment components has been ratified by Australian governmental and community-based organisations.24 Priorities for care in indigenous health are usually established by local health service providers. Since the official notification data may be underestimating the true incidence of N gonorrhoeae and C trachomatis by factors of 4.6 and 4.4 respectively, we believe that there is an urgent need to consider these new data when such priorities are set.

The authors gratefully acknowledge the assistance of Maree Dunn, the clinical and laboratory staff of Territory Health Services, the Royal Women’s Hospital, Melbourne, Westerns Pathology and Queensland Medical Laboratories who were involved in this study. The study was funded in part by a National Health and Medical Research Council project grant.

Contributors: FJB, BAP, CKF, SMG, and SNT were responsible for the original design and conduct of the study; JM and JS provided additional data and assistance in the study. All authors contributed to the writing of the paper.

Estimating the prevalence of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and human papillomavirus infection in indigenous women in northern Australia.

F J Bowden, B A Paterson, J Mein, J Savage, C K Fairley, S M Garland and S N Tabrizi

Sex Transm Infect 1999 75: 431-434
doi: 10.1136/sti.75.6.431

Updated information and services can be found at:
http://sti.bmj.com/content/75/6/431

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/